# MonumenTAL-6 (NCT06208150)

> A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06208150
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Multiple Myeloma
- Interventions: Talquetamab; Pomalidomide; Teclistamab; Elotuzumab; Dexamethasone; Bortezomib
- Enrollment: 838
- Primary outcome: Progression Free Survival (PFS)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Bluesky threads: 3
- X threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=monumental-6-nct06208150